dc.contributor.author |
Bellissima, Brandi L |
|
dc.contributor.author |
Vara, Alisha |
|
dc.contributor.author |
Helsby, Nuala |
|
dc.contributor.author |
Garavan, Fintan |
|
dc.contributor.author |
Tingle, Malcolm D |
|
dc.coverage.spatial |
Ireland |
|
dc.date.accessioned |
2021-09-26T20:47:50Z |
|
dc.date.available |
2021-09-26T20:47:50Z |
|
dc.date.issued |
2021-5 |
|
dc.identifier.issn |
0165-1781 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/56669 |
|
dc.description.abstract |
Clozapine is a uniquely effective antipsychotic indicated for treatment-resistant schizophrenia. However, its use is underutilised and often delayed for years due to potential adverse reactions including myocarditis and cardiomyopathy. The purpose of this study was to conduct a retrospective review of the clinical records of patients initiating clozapine in the Auckland District Health Board (ADHB) region to determine the incidence of clozapine-associated myocarditis and cardiomyopathy and to identify potential risk factors associated with these cardiotoxicities. The incidence of clozapine-associated myocarditis and cardiomyopathy over a two-year period in the ADHB region was 3.8% and 1.3% respectively. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Elsevier BV |
|
dc.relation.ispartofseries |
Psychiatry research |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
cardiomyopathy |
|
dc.subject |
clozapine |
|
dc.subject |
incidence |
|
dc.subject |
myocarditis |
|
dc.subject |
risk factors |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Psychiatry |
|
dc.subject |
clozapine |
|
dc.subject |
myocarditis |
|
dc.subject |
cardiomyopathy |
|
dc.subject |
incidence |
|
dc.subject |
risk factors |
|
dc.subject |
PRACTICE GUIDELINES |
|
dc.subject |
HEART |
|
dc.subject |
SCHIZOPHRENIA |
|
dc.subject |
COMMITTEE |
|
dc.subject |
11 Medical and Health Sciences |
|
dc.subject |
17 Psychology and Cognitive Sciences |
|
dc.title |
Incidence and investigation of potential risk-factors for clozapine-associated myocarditis and cardiomyopathy in a New Zealand cohort. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1016/j.psychres.2021.113873 |
|
pubs.begin-page |
113873 |
|
pubs.volume |
299 |
|
dc.date.updated |
2021-08-16T04:00:26Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/33799127 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
844672 |
|
dc.identifier.eissn |
1872-7123 |
|
dc.identifier.pii |
S0165-1781(21)00170-0 |
|
pubs.number |
113873 |
|